胆管癌内镜治疗新进展
宋家澍1 , 2 , 3 ，张喆1 , 2 , 3 ，马涛1 , 2 , 3 ，李成祥4 ，吕毅1 , 2 , 3
（1 .西安交通大学第一附属医院肝胆外科，陕西 西安，710061 ；2.西安交通大学先进外科技术与工程研究所， 陕西 西安，710061 ；3.陕西省再生医学与外科工程研究中心，陕西 西安；710061 ； 4 .重庆大学输配电装备及系统安全与新技术国家重点实验室，重庆，400030）
浏览次数：112次 下载次数：251次
摘要：
<正>胆管细胞癌（cholangiocarcinoma, CCA）是一种异质性强的恶性肿瘤，其发生位置遍布于毛细胆管至胆总管，可起源于胆道系统的任何部位。在世界范围内，胆管癌占所有消化 道恶性肿瘤的3%，同时也是第二大肝胆胰肿瘤[1- 2]。胆管癌在年龄上好发于60~70岁，在儿童中罕见[3]；亚洲人患病的几率 是白人和黑人的2倍[2]；胆管癌发病率在男女比例上也存在明显差异，SHAIB 等[4]的研究显示男性发病率要比女性高50%。在过去几十年中，胆管癌的发病率在全球范围内逐年上升[5]。 而在我国，胆管癌在消化道恶性肿瘤中居第5位，是导致我国人口死亡的十大恶性肿瘤之一。临床上根据解剖部位， 将胆管癌分为肝内胆管癌、肝门部胆管癌及远端胆管癌三种类型，其中最常见的是肝门部胆管癌（占50%），其次为远 端胆管癌（占40%），肝内胆管癌发病率较低（常低于10%）[6~7]。 NAKEEB 等[8]在汇总了294例胆管癌患者的报告中指出手术切除的肝内、肝门部和远端胆管癌5年生存率分别为44%、 11%和28%，中位生存时间分别为26、19和22 个月。
关键词：
中图分类号：R735.8文献标志码：A文章编号：2096-1413(2017)09-0001-02
参考文献：
[1] OLNES MJ,ERLICH R.A review and update on cholangiocarcinoma [J].Oncology,2004,66(3):167-179.
[2] SHAIB Y,EL-SERAG HB.The epidemiology of cholangiocarcinoma [J].Semin Liver Dis,2004,24(2):115-125.
[3] EVERHART JE, RUHL CE.Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas[J].Gastroenterology,2009,136(4):1134-1144.
[4] SHAIB YH,EL-SERAG HB,DAVILA J A,et al.Risk factors of intrahepatic cholangiocarcinoma in the United States:a case-control study[J]. Gastroenterology,2005,128(3):620-626.
[5] PATEL T.Worldwide trends in mortality from biliary tract malignancies[J].BMC Cancer,2002,2:10.
[6] RAZUMILAVA N,GORES GJ.Cholangiocarcinoma [J].Lancet,2014, 383(9935):2168-2179.
[7] 王荇,李相成.胆管癌姑息治疗的研究进展[J].临床肝胆病杂志, 2016,32(5):1022-1025.
[8] NAKEEB A,PITT HA,SOHN TA,et al.Cholangiocarcinoma.A spectrum of intrahepatic, perihilar,and distal tumors[J].Ann Surg,1996,224(4): 463-475.
[9] MIURA JT,JOHNSTON FM,TSAI S,et al.Chemotherapy for surgically resected intrahepatic cholangiocarcinoma [J].Ann Surg Oncol,2015, 22 (11):3716-3723.
[10] KHAN SA,THOMAS HC,DAVIDSON BR,et al.Cholangiocarcinoma [J].Lancet,2005,366(9493):1303-1314.
[11] KHAN SA,DAVIDSON BR,GOLDIN RD,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update [J].Gut,2012,61 (12):1657-1669.
[12] JARNAGIN WR,SHOUP M.Surgical management of cholangiocarcinoma[J].Semin Liver Dis,2004,24(2):189-199.
[13] NAKEEB A,TRAN KQ,BLACK MJ,et al.Improved survival in resected biliary malignancies[J].Surgery,2002,132(4):555-563,564.
[14] ANDERSON CD,PINSON CW,BERLIN J,et al.Diagnosis and treatment of cholangiocarcinoma[J].Oncologist,2004,9(1):43-57.
[15] BROWN DB.Thermal ablation 2010:unprecedented growth and promise[J].J Vasc Interv Radiol,2010,21(8 Suppl):S177.
[16] FREEMAN ML,GUDA NM.ERCP cannulation:a review of reported techniques[J].Gastrointest Endosc,2005,61(1):112-125.
[17] ANDERSON MA,FISHER L,JAIN R,et al.Complications of ERCP [J].Gastrointest Endosc,2012,75(3):467-473.
[18] PAIELLA S,SALVIA R,RAMERA M,et al.Local ablative strategies for ductal pancreatic cancer (Radiofrequency Ablation,Irreversible Electroporation): A Review[J].Gastroenterol Res Pract,2016:4508376.
[19] STEEL AW,POSTGATE AJ,KHORSANDI S,et al.Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction[J].Gastrointest Endosc,2011,73(1):149-153. [20] DOLAK W,SCHREIBER F,SCHWAIGHOFER H,et al.Endoscopic radiofrequency ablation for malignant biliary obstruction:a nationwide retrospective study of 84 consecutive applications[J].Surg Endosc,2014, 28(3):854-860.
[21] ALVAREZ-SANCHEZ MV,NAPOLEON B.Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety[J].World J Gastroenterol,2016,22(37):8257-8270. [22] OGURA T,ONDA S,SANO T,et al.Evaluation of the safety of endoscopic radiofrequency ablation for malignant biliary stricture using a digital peroral cholangioscope (with videos)[J].Dig Endosc,2017.
[23] CUNNINGHAM D,CHAU I,STOCKEN D D,et al.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J].J Clin Oncol,2009,27(33):5513-5518. [24] VACCARO V,SPERDUTI I,MILELLA M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [J].N Engl J Med,2011,365 (8): 768-769.
[25] GOLBERG A,YARMUSH M L.Nonthermal irreversible electroporation:fundamentals, applications, and challenges [J].IEEE Trans Biomed Eng,2013,60(3):707-714.
[26] BOWER M,SHERWOOD L,LI Y,et al.Irreversible electroporation of the pancreas: definitive local therapy without systemic effects[J].J Surg Oncol,2011,104(1):22-28.
[27] NEUMANN E,ROSENHECK K.Permeability changes induced by electric impulses in vesicular membranes[J].J Membr Biol,1972,10(3):279-290. [28] GLYBOCHKO PV,ALYAEV YG,AMOSOV AV,et al.Irreversible electroporation to treat prostate cancer (Nanoknife)[J].Urologiia,2016(6): 153-157.
[29] PETROU A,MORIS D, PAUL T P,et al.Ablation of the locally advanced pancreatic cancer: An introduction and brief summary of techniques[J].J BUON,2016,21(3):650-658.
[30] ZHANG Z,LI W,PROCISSI D,et al.Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation[J].Nanomedicine (Lond), 2014,9(8):1181-1192. [31] LAMBERT L,HOREJS J,KRSKA Z,et al.Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience[J].Neoplasma, 2016,63(2):269-273.
[32] COROVIC S,BESTER J,MIKLAVCIC D.An e-learning application on electrochemotherapy[J].Biomed Eng Online,2009(8):26.
[33] CEMAZAR M,TAMZALI Y,SERSA G,et al.Electrochemotherapy in veterinary oncology[J].J Vet Intern Med,2008,22(4):826-831.
[34] SERSA G,MIKLAVCIC D,CEMAZAR M,et al.Electrochemotherapy in treatment of tumours[J].Eur J Surg Oncol,2008,34(2):232-240.
[35] VALERIO M,DICKINSON L,ALI A,et al.Nanoknife electroporation ablation trial:A prospective development study investigating focal irreversible electroporation for localized prostate cancer[J].J Urol,2017,197 (3 Pt 1):647-654.